RECOMBINANT HUMAN IgE KAPPA L

Recombinant human IgE (kappa L) protein is a recombinant human IgE antibody with a kappa light chain which recognises Zika virus NS1. It is recommended for use as a standard in assays designed to measure IgE levels, or as a control antibody when using other human antibodies of the same isotype and subclass.

PRODUCT DETAILS – RECOMBINANT HUMAN IgE KAPPA L

• Recombinant human IgE (kappa L) protein is composed of the human Ɛ heavy chain and the Ƙ light chain. The heavy chain is C-terminally His-tagged.
• The antibody recognises Zika virus NS1.
• Produced in mammalian HEK293 cells.
• Purified by immobilised metal affinity chromatography and sterile filtered into Dulbecco’s phosphate buffered saline pH7.4.

BACKGROUND

Antibodies are glycoproteins that bind specific antigens and are produced in response to foreign molecules entering the body. Antibodies are composed of two immunoglobulin (Ig) heavy chains and two Ig light chains. The heavy chain makeup determines the overall class of each antibody. The light chains of an antibody are classified as either kappa (κ) or lambda (λ) based on small differences in their polypeptide sequence. There are two types of light chain in humans, kappa (κ) chain and lambda (λ) chain. Only one type of light chain is present in a typical antibody and individual B-cells in lymphoid tissue either possess kappa or lambda light chains, but never both together. Each light chain is composed of two tandem immunoglobulin domains, one constant (C_L) domain and one variable domain (V_L), which is important for antigen binding. The constant region determines what class (kappa or lambda) the light chain is. The approximate length of a light chain protein is 211-217 amino acids (Janeway et al., 2001).

Zika virus is a flavivirus which is carried by mosquitos and is closely related to Dengue virus. It can cause severe disease in humans, including microcephaly in newborns and Guillain-Barré syndrome in adults. There are currently no specific treatments or vaccines available for Zika virus (Bailey et al., 2018).

REFERENCES

• Bailey et al. (2018). Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nature Communications 9: 4560.
• Janeway CA, Jr. et al. (2001). Immunobiology (5th ed.). Garland Publishing.